Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A gynecologic oncology group ancillary data analysis

Cancer

Volumn 116, Issue 23, 2010, Pages 5407-5414

  Moore, Kathleen N ^a   Tian, Chunqiao ^b,e   McMeekin, D Scott ^a   Thigpen, J Tate ^c   Randall, Marcus E ^d   Gallion, Holly H ^e  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Gynecologic Oncology Group Statistical Office   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Precision Therapeutics Inc   (United States)

Author keywords

ancillary data analysis; chemotherapy; endometrial cancer; Gynecologic Oncology Group; salvage chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RECURRENT CANCER; SALVAGE THERAPY;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 78649559263     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25480     Document Type: Article

References (26)

1. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004; 22: 3902-3908.
2. Randall M, Filiaci V, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006; 24: 36-44.
3. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 62: 278-281.
4. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin +cisplatin versus doxorubicin + 24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004; 15: 1173-1178.
5. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004; 22: 2159-2166. (Pubitemid 41095150)
6. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003; 88: 277-281.
7. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002; 20: 2360-2364.
8. Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 103: 523-526.
9. McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with persistent or recurrent endometrial cancer with translational research: a Gynecologic Oncology Group study. Gynecol Oncol. 2007; 105: 508-516. (Pubitemid 46591977)
10. Markman M, Rothman R, Hakes T, et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9: 389-393.
11. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with those compounds. Gynecol Oncol. 1990; 36: 207-211. (Pubitemid 20061287)
12. Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3808-3813.
13. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2007; 106: 16-22.
14. Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a GOG study. Cancer. 2006; 107: 2197-2205.
15. Rose PG, Blessing JA, Lewandowski GA, et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 63: 101-104.
16. Moore DH, Blessing JA, Dunton C, et al. Evaluation of dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999; 75: 473-475.
17. Plaxe S, Blessing JA, Husseindazeh N, et al. Evaluation of pyrazoloacridine (PZA) (NSC #366140) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002; 84: 241-244.
18. Miller DS, Blessing JA, Lentz SS, et al. Evaluation of topotecan in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002; 87: 247-251.
19. Schilder R, Blessing JA, Pearl ML, et al. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Invest New Drugs. 2004; 22: 343-349.
20. Grendys E, Blessing J, Burger R, et al. A phase II evaluation of flavorpiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2005; 98: 249-253. (Pubitemid 41019113)
21. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004; 22: 3120-3125.
22. Kaplan EL, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
23. Cox DR., Regression models and life-tables. J R Stat Soc B. 1972; 34: 187-220.
24. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009; 112: 543-552.
25. Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a GOG study [abstract]. J Clin Oncol. 2009; 27 (15S pt I): 284S. Abstract 5531.
26. Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer. 1987; 56: 1725.